MiR-133b targets DOT1L, a histone H3 lysine-79 specific N-methyltransferase upregulated in colon cancer cells-derived spheroids, reducing CSC phenotype, and improving sensitivity to 5-FU and L-OHP [48]. Here, DOT1L is linked to malignant colon neoplasm.